Viatris Inc. (VTRS) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Viatris (VTRS) by buying shares or fractional shares at any major US broker, through a healthcare or pharmaceutical ETF that holds it, or as one position in a thematic basket. Viatris is a global healthcare company formed in 2020 by combining Mylan with Pfizer's Upjohn unit, selling generics, biosimilars, and established off-patent brand medicines (including Lipitor, Viagra, and EpiPen) across more than 165 countries. The core thing to understand is that this is a low-multiple, high-cash-flow value name in transition: it is paying down a large post-merger debt load and a dividend while trying to pivot from a slow-growth generics giant toward a more specialty and innovative pipeline, all against pricing pressure and a manufacturing setback at its Indore plant in India.
VTRS stock price
As of 2026-07-14, Viatris Inc. (VTRS) last closed at $16.30, up 78.3% over the past year. Over the past 52 weeks it has traded between $8.74 and $17.39.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Viatris Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Viatris Inc. (VTRS) do?
Viatris was created in November 2020 by merging Mylan with Pfizer's Upjohn business, uniting a large generics and biosimilars operation with a portfolio of well-known, off-patent branded drugs such as Lipitor, Norvasc, Viagra, and EpiPen. It sells across more than 165 countries and reports through a global commercial footprint that spans developed and emerging markets, with a business mix of generics, established brands, and a smaller but growing specialty and pipeline component. Because most of its revenue comes from mature, off-patent medicines, Viatris behaves like a value stock: steady cash generation, a modest valuation multiple, and slow top-line growth rather than the rapid expansion of a patent-protected innovator.
Since the merger, management has divested non-core units (including its OTC and API businesses and a biosimilars deal) and used the proceeds and free cash flow to reduce a large debt load and fund shareholder returns. Full-year 2025 revenue landed around $13.9 to $14.3 billion, down from 2024 partly due to those divestitures, and the company reported a large GAAP net loss driven by non-cash goodwill impairment. A significant overhang in 2025 was an FDA warning letter and import alert at its Indore, India oral-dose facility, which the company estimated cut roughly $370 million from revenue. Looking ahead, Viatris reaffirmed 2026 guidance in the range of about $14.45 to $14.95 billion in revenue and roughly $2.33 to $2.47 in adjusted EPS, and points to a set of near-term regulatory decisions, including a contraceptive patch, a presbyopia eye drop (MR-141), and a non-opioid pain therapy, as catalysts for its pivot toward higher-value products.
What's driving Viatris Inc. (VTRS)?
1. Cash flow, debt reduction, and the dividend
Viatris's investment case rests heavily on free cash flow. The company converts its mature drug portfolio into substantial cash, which it splits between paying down the large debt taken on in the Mylan-Upjohn merger and funding a dividend and buybacks. Steady deleveraging strengthens the balance sheet and lowers risk over time. For value-oriented investors, this cash-return-and-cleanup story, rather than growth, is the main reason to own the stock.
2. Pivot from generics giant to specialty and pipeline
Management is trying to shift the mix from low-margin generics toward higher-value specialty, branded, and novel products. Near-term catalysts include regulatory decisions on a contraceptive patch, the MR-141 presbyopia eye drop, and the MR-107A-02 non-opioid pain therapy, spread across 2026. Success would add growth and durability the generics base lacks. This transition is the central bet on whether Viatris can escape years of flat-to-declining revenue.
3. The Indore facility and manufacturing quality
An FDA warning letter and import alert at the Indore, India oral-dose plant weighed on 2025, with an estimated revenue impact of roughly $370 million and an EBITDA headwind into 2026. Remediating the site and restoring product flow is a concrete swing factor. It is also a reminder that for a generics manufacturer, plant quality and regulatory compliance are core operational risks that can directly dent earnings.
4. Portfolio reshaping and biosimilars
Viatris has actively reshaped its portfolio, divesting the OTC and API businesses and parts of biosimilars while keeping select high-barrier franchises like ophthalmology. A temporary Medicare Part B reimbursement uplift for biosimilars through 2027 is a modest tailwind for its remaining biosimilar partnerships. How well management high-grades the portfolio toward more durable, higher-margin revenue will shape the long-run growth and margin profile.
What are the risks to Viatris Inc. (VTRS)?
The biggest risk is structural: most of Viatris's revenue comes from mature, off-patent medicines facing constant price erosion and competition, which has produced years of flat-to-declining sales and makes growth hard to generate. The Indore FDA warning letter and import alert directly cut revenue and add remediation uncertainty, and a large 2025 GAAP net loss driven by goodwill impairment shows how much intangible value from the merger has been written down. The company still carries meaningful post-merger debt, so cash flow must keep servicing it. The pivot to specialty and pipeline products is unproven and depends on regulatory approvals that may slip or disappoint. Drug-pricing policy, currency swings across its many markets, and integration fatigue add further uncertainty.
How is Viatris Inc. (VTRS) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Viatris Inc.'s investor relations page or your broker.
- Revenue (FY2025): ~$13.9 to $14.3 billion, down from ~$14.7 billion in 2024, partly due to divestitures
- FY2026 revenue guidance: ~$14.45 to $14.95 billion (reaffirmed)
- FY2026 adjusted EPS guidance: ~$2.33 to $2.47
- FY2025 GAAP result: Large net loss (~$3.5 billion) driven mainly by non-cash goodwill impairment
- Valuation profile: Low single-digit forward P/E on adjusted EPS; a classic deep-value pharma multiple
- Capital returns: Pays a dividend and reduces debt from free cash flow; yield has been relatively high
Figures are approximate and tied to the asOf date; verify live numbers (current revenue, guidance, adjusted and GAAP EPS, dividend, and debt levels) before acting. Viatris trades on a low multiple typical of a slow-growth value stock, and its adjusted EPS looks much healthier than its GAAP result because large non-cash impairments hit the reported bottom line. The gap between adjusted and GAAP earnings, plus how much of the low multiple reflects genuine value versus stagnant revenue, is the crux of the debate on the stock.
Who competes with Viatris Inc. (VTRS)?
Large global generics and biosimilars makers
Teva Pharmaceutical is the largest global generics player and Viatris's most direct rival, with a strong US and European footprint and branded franchises like Austedo. Sandoz, a generics and biosimilars pure-play spun out of Novartis, is another key competitor, especially in Europe and biosimilars. Both compete head-to-head with Viatris on price and scale in commodity generics.
Diversified and emerging-market generics
Companies such as Organon (a women's-health-focused Merck spinoff), plus large India-based generics makers like Dr. Reddy's Laboratories, Sun Pharma, and Cipla, and US-listed peers like Amneal, compete across generics and established brands in many of the same markets. Their low-cost manufacturing and broad portfolios keep pricing pressure high across the industry.
Branded and specialty pharma
As Viatris pivots toward specialty and novel products in areas like ophthalmology and pain, it increasingly bumps against branded and specialty drugmakers rather than pure generics rivals. These innovator companies compete on patented products and R&D pipelines, a higher-margin but higher-risk arena that Viatris is only beginning to enter more seriously.
How to invest in Viatris Inc. (VTRS)
There are three common ways to get VTRS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so VTRS sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where VTRS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Viatris Inc. (VTRS)
Viatris is a cheap, cash-generative global pharma using its free cash flow to cut debt and fund a dividend while pivoting toward specialty and pipeline assets. The bull case is durable cash flow and near-term product approvals; the bear case is eroding generics pricing, the Indore plant hit, and years of flat-to-declining revenue.
Build a basket around VTRS with Walnut
Use Viatris Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is VTRS a good stock to buy right now?
+
This depends on your goals, time horizon, and risk tolerance, and it is not investment advice. The bull case is a cheap valuation, strong free cash flow funding debt reduction and a dividend, and near-term product approvals. The bear case is that most revenue comes from mature generics under constant price pressure, growth has been elusive, and the Indore plant issue and merger writedowns add uncertainty. Weigh the value-and-yield appeal against the slow-growth reality.
What does Viatris do?
+
Viatris is a global healthcare company that develops, makes, and sells generic drugs, biosimilars, and established off-patent branded medicines in more than 165 countries. Its portfolio includes well-known names such as Lipitor, Norvasc, Viagra, and EpiPen. It was formed in 2020 by merging Mylan with Pfizer's Upjohn business, and most of its revenue comes from mature, off-patent products rather than new patented drugs.
How was Viatris created?
+
Viatris was formed in November 2020 by combining Mylan, a large generics and biosimilars company, with Upjohn, the off-patent branded-drug unit spun out of Pfizer. The deal brought together Mylan's manufacturing scale with a portfolio of established brands like Lipitor and Viagra, but it also loaded the new company with significant debt that management has been working to reduce ever since.
Why did Viatris report a large loss in 2025?
+
Viatris posted a large GAAP net loss for 2025 driven mainly by non-cash goodwill impairment, meaning it wrote down the accounting value of assets and goodwill carried from the Mylan-Upjohn merger. Impairments reduce reported earnings but do not consume cash. That is why the company's adjusted EPS, which excludes such one-time items, looked far healthier than its GAAP bottom line.
What is the Indore facility issue?
+
The FDA issued a warning letter and import alert covering Viatris's oral finished-dose manufacturing plant in Indore, India, restricting products made there from entering the US market. Viatris estimated the disruption cut roughly $370 million from 2025 revenue and created an earnings headwind into 2026. Remediating the site and restoring product supply is an important operational catalyst to watch.
Does Viatris pay a dividend?
+
Yes. Viatris pays a regular dividend funded from its free cash flow, and its yield has generally been relatively high, reflecting both the payout and a low share price. Alongside the dividend, management uses cash to pay down merger-related debt. Because generics pricing and earnings can shift, it is worth checking the latest declared dividend, payout ratio, and coverage before assuming any yield.
What is Viatris's growth pipeline?
+
Viatris is trying to add growth through specialty and novel products beyond commodity generics. Near-term regulatory decisions in 2026 include a contraceptive patch, the MR-141 eye drop for presbyopia, and the MR-107A-02 non-opioid pain therapy, along with a number of new generic and biosimilar approvals globally. These launches are central to whether the company can move past years of flat-to-declining revenue.
Who are Viatris's main competitors?
+
Its closest large rivals are Teva Pharmaceutical and Sandoz in global generics and biosimilars. It also competes with Organon and major India-based generics makers such as Dr. Reddy's, Sun Pharma, and Cipla, plus US peers like Amneal. As it pushes into specialty products, it increasingly faces branded and specialty drugmakers as well, which compete on patented, higher-margin medicines.
How can I get exposure to Viatris through an ETF?
+
VTRS appears in many broad healthcare, pharmaceutical, and value or dividend-focused ETFs, where it sits among other drugmakers. ETF exposure spreads single-stock risk across dozens of holdings but dilutes how much any single Viatris move affects you. Always check a fund's holdings and weightings before assuming meaningful exposure to Viatris specifically.
What are the main risks of owning VTRS?
+
The core risk is that most revenue comes from mature generics facing steady price erosion, which has made growth hard and kept the multiple low. The Indore FDA issue cut revenue and adds remediation risk, large goodwill writedowns hit reported earnings, and the company still carries meaningful debt. Its pivot to specialty products is unproven and hinges on regulatory approvals, and drug-pricing policy and currency swings add further uncertainty.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Viatris Inc.'s investor relations page or your broker before making investment decisions.